Dimethyl fumarate versus interferon for treatment of relapsing-remitting multiple Sclerosis

被引：0
|
作者：
Sattarnezhad, Neda [1 ]
Healy, Brian C. [1 ,2 ]
Baharnoori, Moogeh [1 ]
Diaz-Cruz, Camilo [1 ]
Stankiewicz, James [1 ]
Weiner, Howard L. [1 ]
Chitnis, Tanuja [1 ,3 ]
机构：
[1] Brigham & Womens Hosp, Partners MS Ctr, Boston, MA 02115 USA
[2] MGH Biostat Ctr, Boston, MA USA
[3] Massachusetts Gen Hosp, Pediat MS Ctr, Boston, MA 02114 USA
来源：
NEUROLOGY | 2017年 / 88卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P6.381
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Characterization of lymphopenia in relapsing-remitting multiple sclerosis patients treated with dimethyl fumarate and fingolimod
    Nakhaei-Nejad, M.
    Barilla, D.
    Lee, C-H.
    Blevins, G.
    Giuliani, F.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 618 - 618
  • [32] Dimethyl Fumarate-Induced Takotsubo Cardiomyopathy in a Patient With Relapsing-Remitting Multiple Sclerosis
    Srichawla, Bahadar S.
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (04)
  • [33] Comparing the impact of dose titration on gastrointestinal tolerability: diroximel fumarate versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis
    Naismith, R. T.
    Badwan, R.
    Chen, H.
    Lyons, J.
    Miller, C.
    Scaramozza, M.
    Shankar, S. L.
    Antezana, A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 587 - 588
  • [34] Diroximel fumarate and dimethyl fumarate demonstrate early clinical and radiological efficacy in relapsing-remitting multiple sclerosis
    Singer, Barry A.
    Shafer, S. James
    Arnold, Douglas L.
    Bowen, James D.
    LaGanke, Christopher
    Chen, Hailu
    Hanna, Jerome
    Miller, Catherine
    Leigh-Pemberton, Richard
    Naismith, Robert T.
    [J]. NEUROLOGY, 2020, 94 (15)
  • [35] Cost Effectiveness of Fingolimod, Teriflunomide, Dimethyl Fumarate and Intramuscular Interferon-β1a in Relapsing-Remitting Multiple Sclerosis
    Xinke Zhang
    Joel W. Hay
    Xiaoli Niu
    [J]. CNS Drugs, 2015, 29 : 71 - 81
  • [36] Cost Effectiveness of Fingolimod, Teriflunomide, Dimethyl Fumarate and Intramuscular Interferon-β1a in Relapsing-Remitting Multiple Sclerosis
    Zhang, Xinke
    Hay, Joel W.
    Niu, Xiaoli
    [J]. CNS DRUGS, 2015, 29 (01) : 71 - 81
  • [37] Interferon-β treatment and the natural history of relapsing-remitting multiple sclerosis
    Koch, Marcus
    Mostert, Jop
    De Keyser, Jacques
    Tremlett, Helen
    Filippini, Graziella
    [J]. ANNALS OF NEUROLOGY, 2008, 63 (01) : 125 - 126
  • [38] Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis
    Cocco, Eleonora
    Marrosu, Maria Giovanna
    [J]. THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2015, 11 : 759 - 766
  • [39] Comparison of dimethyl fumarate as initial and secondary treatment for relapsing-remitting multiple sclerosis: a retrospective national cohort study
    Granqvist, M.
    Frisell, T.
    Piehl, F.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 690 - 690
  • [40] The Effectiveness of Dimethyl Fumarate Monotherapy in the Treatment of Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis
    Kawalec, Pawel
    Mikrut, Alicja
    Wisniewska, Natalia
    Pilc, Andrzej
    [J]. CURRENT NEUROPHARMACOLOGY, 2014, 12 (03) : 256 - 268
12345